Abstract
Purpose
Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. However, efficacy and survival for these two settings have not been compared, leaving it unclear whether these two populations can be included in the same clinical trials. Moreover, prognostic factors for patients who are recommended to receive docetaxel/pemetrexed monotherapy are largely unknown.
Methods
Docetaxel or pemetrexed was administered to 67 EGFR wild-type patients as a second-line treatment following one platinum-based combination chemotherapy and to 17 EGFR mutant patients as a third-line treatment following EGFR tyrosine kinase inhibitors and one platinum-based combination chemotherapy. Docetaxel and pemetrexed were administered at 60 and 500 mg/m2, respectively, every 3 weeks until disease progression, intolerable toxicity, or patient refusal. Overall survivals (OSs) between the two groups were compared using the log-rank test, and prognostic factors were evaluated via Cox’s proportional hazards models.
Results
The median OS was 345.5 days in the EGFR wild-type second-line group and 616 days in the EGFR mutant third-line group. Multivariate analyses revealed that the stage before first-line treatment, performance status, and EGFR status were significant prognostic factors.
Conclusions
When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies.
Similar content being viewed by others
References
American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta
Köhler J, Schuler M (2013) Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36:510–518
Vijayvergia N, Mehra R (2014) Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74:437–446
Berge EM, Doebele RC (2014) Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 41:110–125
Imielinski M, Greulich H, Kaplan B et al (2014) Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 124(4):1582–1586
Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–180
Shepherd F, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 18:2095–2103
Fossella F, DeVore R, Kerr R et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362
Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597
Mok TS, Wu Y, Nakagawa K et al (2014) Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomized IMPRESS study. Ann Oncol 25(Supplement 5):v1–v4 (LBA2_PR)
NCCN.org. NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer version 1.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
The Japan Lung Cancer Society. Guidelines for the treatment of lung cancer. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3. (in Japanese)
Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673
Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 15:143–155
Hanna NH, Kaiser R, Sullivan RN et al (2013) Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31(suppl) (abstr 8034)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no financial or personal conflicts of interest.
Rights and permissions
About this article
Cite this article
Shukuya, T., Ko, R., Mori, K. et al. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. Cancer Chemother Pharmacol 76, 771–776 (2015). https://doi.org/10.1007/s00280-015-2843-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2843-3